{"title":"Association of XRCC6 -61 C > G and XRCC7 6721G > T polymorphisms with susceptibility to pediatric acute lymphoblastic leukemia.","authors":"Mani Ramzi, Soodabeh Zare, Nasrin Noshadi, Ghasem Nikfar, Zahed Karimi, Mahdiyar Iravani Saadi","doi":"10.1186/s43046-026-00402-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute lymphoblastic leukemia (ALL) is the most frequent malignancy in children. The XRCC6 and XRCC7 genes play a key role in the nonhomologous end-joining (NHEJ) repair process and may influence susceptibility to ALL. The aim of this study is to evaluate the polymorphisms XRCC6 -61 C > G (rs2267437) and XRCC7 6721G > T (rs7003908) in children with ALL.</p><p><strong>Materials and methods: </strong>Genomic DNA was extracted from the buffy coat from whole blood samples of patients. Genotyping of XRCC6 -61 C > G and XRCC7 6721G > T polymorphisms was performed by PCR followed by restriction fragment length polymorphism (PCR-RFLP) using specific restriction enzymes (BanI and Pvu II).</p><p><strong>Results: </strong>In this investigation significant associations were discovered between XRCC6 -61 C > G genotypes CC (P = 0.006) and CG (P = 0.01) with ALL patients. It is important to note that while the CC genotype association remained significant after Bonferroni correction (P < 0.01), the CG genotype association was nominal (P between 0.01 and 0.05) and should be interpreted with caution. XRCC7 6721G > T genotypes GT (P = 0.02) and TT (P = 0.05) were significantly associated with ALL in males and females, respectively. In ALL patients with B-Cell subtype, XRCC6 -61 C > G genotypes CC (P = 0.04), GC (P = 0.05), and C allele (P = 0.05) showed significant associations. XRCC7 6721G > T genotypes GT (P = 0.003) and TT (P = 0.05) were also significantly associated in B-Cell ALL. Significant associations were observed for XRCC6 -61 C > G genotype CC (P = 0.04) and C allele (P = 0.03) in ALL patients with favorable cytogenetic abnormalities.</p><p><strong>Conclusions: </strong>In conclusion, our findings suggest that the XRCC6 -61 C > G and XRCC7 6721G > T polymorphisms may be associated with susceptibility to pediatric ALL, with potential lineage-specific and cytogenetic context-dependent effects. However, given the exploratory nature of our subgroup analyses and the statistical limitations, these results should be interpreted cautiously. Large-scale, multi-center studies with functional validation are needed to confirm these associations and elucidate the underlying mechanisms.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"38 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675453/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-026-00402-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Acute lymphoblastic leukemia (ALL) is the most frequent malignancy in children. The XRCC6 and XRCC7 genes play a key role in the nonhomologous end-joining (NHEJ) repair process and may influence susceptibility to ALL. The aim of this study is to evaluate the polymorphisms XRCC6 -61 C > G (rs2267437) and XRCC7 6721G > T (rs7003908) in children with ALL.
Materials and methods: Genomic DNA was extracted from the buffy coat from whole blood samples of patients. Genotyping of XRCC6 -61 C > G and XRCC7 6721G > T polymorphisms was performed by PCR followed by restriction fragment length polymorphism (PCR-RFLP) using specific restriction enzymes (BanI and Pvu II).
Results: In this investigation significant associations were discovered between XRCC6 -61 C > G genotypes CC (P = 0.006) and CG (P = 0.01) with ALL patients. It is important to note that while the CC genotype association remained significant after Bonferroni correction (P < 0.01), the CG genotype association was nominal (P between 0.01 and 0.05) and should be interpreted with caution. XRCC7 6721G > T genotypes GT (P = 0.02) and TT (P = 0.05) were significantly associated with ALL in males and females, respectively. In ALL patients with B-Cell subtype, XRCC6 -61 C > G genotypes CC (P = 0.04), GC (P = 0.05), and C allele (P = 0.05) showed significant associations. XRCC7 6721G > T genotypes GT (P = 0.003) and TT (P = 0.05) were also significantly associated in B-Cell ALL. Significant associations were observed for XRCC6 -61 C > G genotype CC (P = 0.04) and C allele (P = 0.03) in ALL patients with favorable cytogenetic abnormalities.
Conclusions: In conclusion, our findings suggest that the XRCC6 -61 C > G and XRCC7 6721G > T polymorphisms may be associated with susceptibility to pediatric ALL, with potential lineage-specific and cytogenetic context-dependent effects. However, given the exploratory nature of our subgroup analyses and the statistical limitations, these results should be interpreted cautiously. Large-scale, multi-center studies with functional validation are needed to confirm these associations and elucidate the underlying mechanisms.
期刊介绍:
As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.